Ocugen FY2026 Earnings Forecast Raised by Noble Financial

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at Noble Financial raised their FY2026 earnings estimates for Ocugen in a note issued to investors on Wednesday, November 11th. Noble Financial analyst R. Leboyer now forecasts that the company will earn ($0.16) per share for the year, up from their prior forecast of ($0.26). The consensus estimate for Ocugen’s current full-year earnings is ($0.23) per share.

Several other research firms have also commented on OCGN. Weiss Ratings restated a “sell (d-)” rating on shares of Ocugen in a report on Wednesday, November 4th. Wall Street Zen raised shares of Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ocugen presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Ocugen Price Performance

Shares of Ocugen stock opened at $0.87 on Friday. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 4.17. Ocugen has a 1 year low of $0.69 and a 1 year high of $2.73. The firm’s 50-day moving average is $0.95 and its two-hundred day moving average is $1.39.

Institutional Investors Weigh In On Ocugen

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Ocugen during the 2nd quarter worth $41,314,000. Hennion & Walsh Asset Management Inc. raised its holdings in Ocugen by 121.7% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 2,830,397 shares of the company’s stock worth $4,331,000 after purchasing an additional 1,553,672 shares in the last quarter. Bank of America Corp DE bought a new position in Ocugen in the second quarter worth about $3,046,000. Bank of New York Mellon Corp bought a new position in Ocugen in the second quarter worth about $1,238,000. Finally, Headlands Technologies LLC lifted its position in shares of Ocugen by 527.1% during the second quarter. Headlands Technologies LLC now owns 511,575 shares of the company’s stock valued at $783,000 after buying an additional 429,997 shares during the last quarter. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Ocugen

In other news, CEO Shankar Musunuri sold 57,264 shares of Ocugen stock in a transaction on Friday, October 9th. The stock was sold at an average price of $0.95, for a total value of $54,400.80. Following the transaction, the chief executive officer directly owned 1,030,771 shares in the company, valued at approximately $979,232.45. This trade represents a 5.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,051,982 shares of company stock worth $1,088,801. 3.95% of the stock is currently owned by company insiders.

Ocugen Company Profile

Ocugen, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases and other eye conditions. Its approach includes modifier gene therapies designed to address multiple genetic causes of disease, rather than targeting a single mutation. The company’s clinical programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease. These programs are investigational and are not approved treatments.